HC Wainwright Has Bullish Forecast for AVDL Q1 Earnings

Key Points

• HC Wainwright has raised its Q1 2026 earnings estimate for Avadel Pharmaceuticals to $0.17 per share, up from a previous estimate of $0.13, while maintaining a "Buy" rating and a price target of $36.00.
• Avadel Pharmaceuticals recently reported Q2 earnings of $0.10 per share, significantly exceeding analysts' expectations of $0.02 and experiencing a robust revenue increase of 64.1% year-over-year.
• The stock currently holds a consensus rating of "Buy" with an average price target of $20.86, and notable recent ratings upgrades have come from firms including Wall Street Zen and UBS Group.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a research note issued to investors on Friday, September 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.17 per share for the quarter, up from their prior estimate of $0.13. HC Wainwright currently has a "Buy" rating and a $36.00 target price on the stock. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals' Q2 2026 earnings at $0.19 EPS and Q4 2026 earnings at $0.26 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.08. The business had revenue of $68.13 million during the quarter, compared to analysts' expectations of $60.28 million. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The business's revenue was up 64.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

A number of other research firms have also recently weighed in on AVDL. Wells Fargo & Company raised Avadel Pharmaceuticals to a "hold" rating in a research report on Wednesday, September 3rd. Zacks Research raised Avadel Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 8th. Wall Street Zen raised Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Avadel Pharmaceuticals in a report on Friday, August 8th. Finally, Lifesci Capital raised Avadel Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, September 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Avadel Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $20.86.

Avadel Pharmaceuticals Stock Performance

Avadel Pharmaceuticals stock traded down $0.46 during mid-day trading on Monday, reaching $15.40. 1,463,911 shares of the company were exchanged, compared to its average volume of 1,389,380. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $16.66. The firm's 50-day simple moving average is $12.67 and its two-hundred day simple moving average is $9.99. The firm has a market cap of $1.50 billion, a PE ratio of -513.33 and a beta of 1.58.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in Avadel Pharmaceuticals by 164.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $29,000 after buying an additional 2,055 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Avadel Pharmaceuticals during the 2nd quarter valued at $65,000. Tower Research Capital LLC TRC grew its holdings in Avadel Pharmaceuticals by 217.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company's stock valued at $78,000 after buying an additional 6,025 shares during the last quarter. Exencial Wealth Advisors LLC acquired a new stake in Avadel Pharmaceuticals during the 1st quarter valued at $82,000. Finally, Thoroughbred Financial Services LLC acquired a new stake in Avadel Pharmaceuticals during the 1st quarter valued at $82,000. 69.19% of the stock is owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.